Importance of treating acne sequelae in skin of color: 6‐month phase IV study of trifarotene with an appropriate skincare routine including UV protection in acne‐induced post‐inflammatory hyperpigmentation

Author:

Alexis Andrew1,Del Rosso James Q.2,Forman Seth3,Martorell Antonio4,Browning John5,Laquer Vivian6,Desai Seemal R.78,York Jean Philippe9,Chavda Rajeev10ORCID,Dhawan Sunil11,Moore Angela Y.1213,Stein‐Gold Linda14

Affiliation:

1. Department of Dermatology Weill Cornell Medical College New York NY USA

2. JDR Dermatology Research Las Vegas NV USA

3. ForCare Medical Center Tampa FL USA

4. Hospital de Manises Valencia Spain

5. Baylor College of Medicine Houston TX USA

6. First OC Dermatology Research Inc. Fountain Valley CA USA

7. Innovative Dermatology Plano TX USA

8. Department of Dermatology The University of Texas Southwestern Medical Center Dallas TX USA

9. Galderma Laboratories, LP Dallas TX USA

10. Galderma Lausanne Switzerland

11. Center for Dermatology Clinical Research, Inc. Fremont CA USA

12. Baylor University Medical Center Dallas TX USA

13. Arlington Research Center Arlington TX USA

14. Henry Ford Medical Center West Bloomfield MI USA

Abstract

AbstractBackgroundAcne‐induced hyperpigmentation (AIH) may accompany acne vulgaris (AV) inflammation in all skin phototypes. Trifarotene has shown depigmenting properties in vivo. This study evaluated trifarotene plus skincare because it is increasingly recognized that holistic AV management should include skincare and treatments.MethodsThis is a phase IV double‐blind, parallel‐group study of patients (13–35 years) with moderate AV and AIH treated with trifarotene (N = 60) or vehicle (N = 63) plus skincare regimen (moisturizer, cleanser, and sunscreen) for 24 weeks. Assessments included the AIH overall disease severity (ODS) score, post‐AV hyperpigmentation index (PAHPI), exit interviews, photography, and acne assessments. Standard safety assessments were included.ResultsTrifarotene 50 μg/g cream improved significantly from baseline in ODS score versus vehicle (−1.6 vs. −1.1, P = 0.03) at Week 12, but scores were comparable between groups at Week 24 (primary endpoint). Trifarotene had a better reduction in PAHPI score at Week 24 (−18.9% vs. −11.3% vehicle, P < 0.01). Lesion count reductions were higher with trifarotene at Week 12 versus vehicle (P < 0.001) and at Week 24 (P < 0.05), as were IGA success rates versus vehicle at Weeks 12 (P < 0.05) and 24 (P < 0.05). Patients agreed that the skincare regimen contributed to less irritation, making treatment adherence easier. Photography showed improvements in pigmentation and erythema across all skin types. AEs were more common in the vehicle group versus trifarotene (30.2 vs. 16.7%, respectively).ConclusionsIn all skin phototypes, there was more rapid improvement in the ODS and PAHPI scores with trifarotene by Weeks 12 and 24, respectively. The combination of trifarotene and skincare correlated with high patient satisfaction and adherence to the treatment protocol.

Funder

Galderma

Publisher

Wiley

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3